Diabetes Drug Could Be Re-purposed to Help End Transplant Rejection

News   Nov 22, 2017 | Original story from Queen Mary University of London (QMUL)

 
 Diabetes Drug Could Be Re-purposed to Help End Transplant Rejection
 
 
 

RELATED ARTICLES

Calidi Biotherapeutics, Inc. Announces its Corporate Vision in Groundbreaking Cancer Drug Development

News

Calidi Biotherapeutics, Inc., formerly StemImmune, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, announced a focused effort to advance its oncolytic virus drug development.

READ MORE

Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca

News

New programs added in respiratory and cardio-metabolic diseases.

READ MORE

Lunaphore and Vitro Sign Collaboration Agreement

News

Companies announce a collaboration agreement to develop In Situ Hybridization (ISH) protocols for RNA and DNA targets in tissue using reagents provided by Vitro on Lunaphore’s rapid autostaining platform.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy